What's Happening?
Delcath Systems has announced the presentation of results from the CHOPIN Phase 2 trial at the ESMO 2025 Congress. The trial, led by Principal Investigator Ellen Kapiteijn, MD, evaluated the safety and efficacy of combining systemic ipilimumab and nivolumab with Delcath's CHEMOSAT Hepatic Delivery System for treating metastatic uveal melanoma. The study aims to assess the potential of high-dose chemotherapy delivered directly to the liver while minimizing systemic exposure and side effects.
Why It's Important?
The CHOPIN trial represents a significant advancement in the treatment of metastatic uveal melanoma, a challenging cancer with limited treatment options. Delcath's approach of delivering chemotherapy directly to the liver could improve tumor response rates while reducing systemic toxicity. The trial's results could pave the way for new liver-directed therapies, offering hope to patients with unresectable hepatic metastases.
What's Next?
The presentation of the CHOPIN trial results at the ESMO Congress will provide an opportunity for further discussion and evaluation by the medical community. Delcath plans to continue its research and development efforts to expand the use of its CHEMOSAT system in treating various liver cancers.
